Talphera, Inc. (TLPH) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Talphera, Inc. is a specialty pharmaceutical company focused on developing innovative therapies for medically supervised settings. The company's primary resource allocation is dedicated to Niyad, a regional anticoagulant for the dialysis circuit, which has received Breakthrough Device Designation from the FDA. The company also holds rights to LTX-608 (nafamostat formulation) and is evaluating the discontinuation of two pre-filled syringe candidates (Fedsyra and a phenylephrine product). As of August 5, 2026, there were 51,905,796 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $27,000 |
| Net Loss | $(4.31) million | $(6.87) million | $(6.08) million |
| Operating Expenses | $3.92 million | $7.87 million | $6.64 million |
| Cash & Short-Term Investments | $17.08 million (as of June 30, 2026) | ||
| Cash Used in Operating Activities | $(7.32) million (YTD 2026) | ||
| Accumulated Deficit | $(478.39) million |
Note: All figures in millions unless otherwise noted. Revenue was $0 for the current period compared to $27,000 in the prior year period.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2026, increased to $6.87 million from $6.08 million in the same period in 2025. This was driven by higher operating expenses.
- R&D Expense Growth: Research and development expenses increased by 25% year-over-year (YTD) to $3.34 million, primarily due to higher Niyad development costs reflecting increased patient enrollment in the NEPHRO CRRT study.
- SG&A Expense Growth: Selling, general, and administrative expenses increased by 14% YTD to $4.53 million, driven by Niyad market research, increased compensation/bonuses, and stock-based compensation, partially offset by lower legal fees.
- Warrant Liability Volatility: The company recorded a $0.66 million gain on the change in fair value of warrant liability for the six months ended June 30, 2026, compared to a $0.30 million gain in the prior year period. This fluctuation is primarily due to changes in the company's stock price.
- Cash Position: Cash and cash equivalents decreased from $5.89 million at year-end 2025 to $0.74 million at June 30, 2026, though total liquid assets (including short-term investments) remained at $17.08 million.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash resources are not expected to fund operations for the next twelve months. Additional capital is required to fund planned operations, including the Niyad clinical trial.
- Financing Needs: The company plans to seek additional capital through public or private equity offerings, debt securities, or strategic collaborations. Failure to secure funding could force workforce reductions or delays in clinical trials.
- Clinical Progress: The Niyad NEPHRO CRRT registrational trial is ongoing, with enrollment completion expected in 2026. The company recently achieved a target price milestone triggering the third closing of its April 2025 private placement.
- Strategic Transactions: Following the announcement of primary endpoint achievement for the NEPHRO CRRT study, CorMedix, Inc. holds a 60-day Right of First Negotiation to acquire 100% of Talphera.
- Discontinued Operations: The company expects lower payments from the sale of future payments related to DSUVIA, as the licensee (Alora) has discontinued sales efforts to non-DoD customers and requested withdrawal of the DSUVIA NDA.
- Supply Chain Risks: The company relies on single sources of supply for nafamostat active pharmaceutical ingredients and finished goods located outside the U.S. (Japan and China), exposing it to tariffs and trade restrictions.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash exhaustion and the status of any new financing agreements or strategic partnerships.
- CorMedix Negotiations: Monitor the outcome of the 60-day exclusivity period with CorMedix regarding a potential acquisition.
- Clinical Trial Enrollment: Confirm the pace of patient enrollment in the Niyad NEPHRO CRRT study to ensure the 2026 completion target remains viable.
- DSUVIA Royalties: Assess the likelihood of receiving any remaining payments from the DSUVIA sale given the licensee's withdrawal of the NDA.
- Supply Chain Mitigation: Review progress on securing alternative manufacturing sources outside of Asia to mitigate tariff and geopolitical risks.